Cadrenal Therapeutics, Inc. Logo

Cadrenal Therapeutics, Inc.

Developing novel anticoagulant therapies for high-risk cardiovascular patients.

CVKD | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
822 A1A NORTH, 32082 PONTE VEDRA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing novel anticoagulant therapies to address critical gaps in cardiovascular care. The company's mission is to create safer and more effective treatments with greater predictability and control, thereby reducing the risks of both clotting and bleeding. Its clinical-stage pipeline includes two primary assets: tecarfarin, an oral vitamin K antagonist for chronic use, and frunexian, a parenteral Factor XIa inhibitor for acute hospital settings. Cadrenal targets underserved, high-risk patient populations, including those with end-stage kidney disease and atrial fibrillation, as well as patients with implanted cardiac devices, aiming to reshape the standards of care in anticoagulation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cadrenal Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cadrenal Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cadrenal Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea 291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America ABUS

Talk to a Data Expert

Have a question? We'll get back to you promptly.